Literature DB >> 23682797

Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes.

So Hun Kim1, Seung Hwan Lee, Ki Yong Ahn, Dong Hoon Lee, Young Ju Suh, Soon Gu Cho, Yun Jin Choi, Dae Hyung Lee, Seung Youn Lee, Seong Bin Hong, Yong Seong Kim, Justin Y Jeon, Moonsuk Nam.   

Abstract

OBJECTIVE: Chemerin, a recently identified adipokine, has been linked to adiposity, insulin resistance, metabolic syndrome risk factors and inflammation. Here, we evaluated whether a 12-week lifestyle intervention in overweight and obese adults with type 2 diabetes could significantly affect the average blood glucose and serum chemerin levels over time.
DESIGN: Thirty-five overweight or obese subjects with type 2 diabetes were randomized to receive intensive lifestyle modification including supervised exercise sessions or usual care for 12 weeks. Anthropometric and clinical data were collected before the intervention and after 12 weeks.
RESULTS: Lifestyle intervention induced a significant decrease in HbA1c (-1·0 ± 0·5 vs 0·1 ± 0·6%, P < 0·001), BMI, total body fat content, serum lipocalin-2 and chemerin levels (-8·1 ± 21·6 vs + 8·2 ± 15·9 ng/ml, P = 0·021) and a significant increase in VO2 max after 12 weeks compared to the usual care group. Baseline chemerin levels were positively correlated with the homoeostasis model of assessment of insulin resistance (HOMA-IR), fasting insulin and the high-sensitivity C-reactive protein (hsCRP) and negatively correlated with insulin sensitivity index (ISI). Changes in the chemerin concentration during 12 weeks were independently negatively correlated with changes in ISI and positively correlated with changes in fasting plasma glucose, total cholesterol and lipocalin-2 levels.
CONCLUSIONS: A 12-week intensive lifestyle intervention significantly decreased serum chemerin level compared to usual care. Decrease in serum chemerin level was associated with improved insulin sensitivity, and this may be involved in the beneficial effects of lifestyle intervention in overweight and obese type 2 diabetic patients.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23682797     DOI: 10.1111/cen.12249

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  20 in total

1.  Exercise-induced lowering of chemerin is associated with reduced cardiometabolic risk and glucose-stimulated insulin secretion in older adults.

Authors:  S K Malin; S D Navaneethan; A Mulya; H Huang; J P Kirwan
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

2.  Effect of an acute bout of aerobic exercise on chemerin levels in obese adults.

Authors:  Jesse W Lloyd; Kristin A Evans; Kristy M Zerfass; Michael E Holmstrup; Jill A Kanaley; Stefan Keslacy
Journal:  Diabetes Metab Syndr       Date:  2015-05-05

3.  Association of serum chemerin and inflammatory factors with type 2 diabetes macroangiopathy and waist-to-stature ratio.

Authors:  Mengxue Yang; Xue Zhou; Jie Xu; Bo Yang; Jie Yu; Qihai Gong; Xuan Zhang; Xiaohua Sun; Qun Zhang; Jinying Xia; Jianhui Li
Journal:  Bosn J Basic Med Sci       Date:  2019-11-08       Impact factor: 3.363

Review 4.  Chemerin/chemR23 axis in inflammation onset and resolution.

Authors:  Francesco Mariani; Luca Roncucci
Journal:  Inflamm Res       Date:  2014-12-30       Impact factor: 4.575

5.  Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis.

Authors:  Ya Li; Bingyin Shi; Sheli Li
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

6.  Diet-induced increases in chemerin are attenuated by exercise and mediate the effect of diet on insulin and HOMA-IR.

Authors:  Jesse W Lloyd; Kristy M Zerfass; Ebony M Heckstall; Kristin A Evans
Journal:  Ther Adv Endocrinol Metab       Date:  2015-10       Impact factor: 3.565

7.  Cardiopulmonary fitness, adiponectin, chemerin associated fasting insulin level in colorectal cancer patients.

Authors:  Ki-Yong Ahn; Mi Kyung Lee; Dong-Il Kim; Jihye Park; Jihee Min; Hyuk In Yang; Junga Lee; Minsuk Oh; Joongbae An; Ji-Won Lee; Sang Hui Chu; Jeffrey A Meyerhardt; Nam-Kyu Kim; Justin Y Jeon
Journal:  Support Care Cancer       Date:  2016-02-05       Impact factor: 3.603

8.  Serum Chemerin Concentrations Associate with Beta-Cell Function, but Not with Insulin Resistance in Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Erifili Hatziagelaki; Christian Herder; Anastasia Tsiavou; Tom Teichert; Athina Chounta; Peter Nowotny; Giovanni Pacini; George Dimitriadis; Michael Roden
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

Review 9.  Adiponectin: an adipokine with protective features against metabolic syndrome.

Authors:  Maryam Esfahani; Ahmad Movahedian; Mostafa Baranchi; Mohammad Taghi Goodarzi
Journal:  Iran J Basic Med Sci       Date:  2015-05       Impact factor: 2.699

10.  Adipocytokines, metabolic syndrome, and exercise.

Authors:  Philip D Chilibeck; Faustino R Pérez-López; Peter F Bodary; Eun Seok Kang; Justin Y Jeon
Journal:  Int J Endocrinol       Date:  2014-03-03       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.